Meeting Banner
Abstract #0969

Using Proton MRSI to Predict Response to Vorinostat Treatment in Recurrent GBM

Li Wei1, Scott N. Hwang2, Andrew H. Miller3, Ying Guo4, Daniel Brat5, 6, Chad A. Holder2, Xiaoping P. Hu1, Jeffrey J. Olson7, Hyunsuk Shim2, 6

1Department of Biomedical Engineering, Emory University, Atlanta, GA, United States; 2Department Radiology and Imaging Science, Emory University, Atlanta, GA, United States; 3Department of Psychiatry, Emory University, Atlanta, GA, United States; 4Department of Biostatistics, school of public health, Emory University, Atlanta, GA, United States; 5Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, United States; 6Winship Cancer Institute, Emory University, Atlanta, GA, United States; 7Department of Neurosurgery, Emory University, Atlanta, GA, United States


Epigenetic modifications are now recognized as a frequent development in the early phases of tumorigenesis, however, they may be readily reversible by epigenetic drugs such as inhibitors of histone deacetylases. In this study, we detected metabolites changes in GBM tumor to SAHA treatment by magnetic resonance spectroscopic imaging (MRSI). The result shows increased NAA, mI and Cre and decreased Cho and Lac/lipids around the tumor area only in responders. This suggests that MRSI can distinguish responders (normalization/restoration of tumor metabolites towards normal brain-like metabolism) from non-responders.

Keywords